June 18, 2021
By Alec Doherty
Real Endpoints Marketplace for addressing high-cost orphan medical benefit drugs is included in MIT’s white paper on emerging market solutions to address coverage and reimbursement challenges faced by durable cell and gene therapies.
Click here to read the article.
